Altimmune Management

How has Vipin Garg's remuneration changed compared to Altimmune's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$101m
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$5m	US$620k	-US$88m
Sep 30 2023	n/a	n/a	-US$78m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$580k	-US$85m
Sep 30 2022	n/a	n/a	-US$87m
Jun 30 2022	n/a	n/a	-US$97m
Mar 31 2022	n/a	n/a	-US$102m
Dec 31 2021	US$3m	US$566k	-US$97m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$1m	US$514k	-US$49m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$815k	US$500k	-US$21m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$34m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$44k	-US$42m

Compensation vs Market: Vipin's total compensation ($USD5.48M) is above average for companies of similar size in the US market ($USD2.34M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.

CEO

Vipin Garg (66 yo)

6yrs

Tenure

US$5,482,089

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Vipin Garg	President	6yrs	US$5.48m	0.41% $ 2.1m
Matthew Harris	Chief Medical Officer	5.3yrs	US$2.24m	0.078% $ 405.1k
Raymond Jordt	Chief Business Officer	1.8yrs	US$2.94m	0.021% $ 107.8k
Andrew Shutterly	Acting CFO	1.8yrs	no data	0.016% $ 83.6k
Bertrand Georges	Chief Technology Officer	7.5yrs	no data	no data
M. Roberts	Chief Scientific Officer	11.9yrs	US$1.41m	0.061% $ 318.4k
Tony Blandin	Vice President of Quality & Compliance Management	2.8yrs	no data	no data

5.3yrs

Average Tenure

65yo

Average Age

Experienced Management: ALT's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Vipin Garg	President	6yrs	US$5.48m	0.41% $ 2.1m
Mitchel Sayare	Independent Chairman	14.6yrs	US$119.68k	0.037% $ 193.7k
John Gill	Independent Director	20.3yrs	US$103.68k	0.0039% $ 20.4k
Philip Hodges	Independent Director	7.5yrs	US$115.68k	0.012% $ 64.1k
Klaus Schafer	Independent Director	7.5yrs	US$104.68k	0.013% $ 67.5k
Catherine Sohn	Independent Director	1.7yrs	US$273.47k	0% $ 0
Wayne Pisano	Independent Director	6.3yrs	US$108.68k	0.012% $ 62.5k
Caroline Apovian	Member of Obesity Scientific Advisory Board	2.3yrs	no data	no data
Diane Jorkasky	Independent Director	4.5yrs	US$95.68k	0% $ 0
Rohit Loomba	Member of Mash Scientific Advisory Board	2.3yrs	no data	no data
Mazen Noureddin	Member of Mash Scientific Advisory Board	2.3yrs	no data	no data
Naga Chalasani	Member of Mash Scientific Advisory Board	2.3yrs	no data	no data

5.3yrs

Average Tenure

71.5yo

Average Age

Experienced Board: ALT's board of directors are considered experienced (5.3 years average tenure).

Altimmune Management

Management criteria checks 2/4

Key information

Recent management updates

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

President exercised options and sold US$115k worth of stock

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

President exercised options and sold US$106k worth of stock

Recent updates

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer

Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity

Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune

Consider Buying Potential Takeover Target Altimmune

Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Altimmune, Inc., Annual General Meeting, Sep 26, 2024

Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions

Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers

Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024

Buy Altimmune's Potential Market Disruption With Pemvidutide

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023

Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

President exercised options and sold US$115k worth of stock

Thoroughly Derisked, Altimmune Is Now A Great Buy

Price target increased by 11% to US$21.29

Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash)

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 29%

Altimmune, Inc., Annual General Meeting, Sep 28, 2023

Consensus revenue estimates increase by 11%

Price target decreased by 21% to US$19.38

Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Price target decreased by 11% to US$26.25

Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 11% to US$26.25

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

President exercised options and sold US$106k worth of stock

Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer

Independent Director exercised options and sold US$248k worth of stock

Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Reassessing Altimmune

Altimmune sets new 52-week high on rising volume

Consensus forecasts updated

Altimmune, Inc., Annual General Meeting, Sep 29, 2022

Price target increased to US$24.86

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Altimmune Q2 2022 Earnings Preview